FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of July 2024
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX TO EXHIBITS
1.
AstraZeneca prices a €1.4bn bond offering
30 July 2024 07:00 BST
AstraZeneca prices €1.4 billion bond offering
AstraZeneca PLC (the Company) announces that, on 29 July 2024, its wholly owned subsidiary AstraZeneca Finance LLC, successfully priced two tranches of Eurobonds totalling €1.4 billion (the Offering). The Offering is expected to close on 5 August 2024, subject to customary closing conditions.
The Offering consisted of the following notes, issued by AstraZeneca Finance LLC and fully and unconditionally guaranteed by the Company:
· €650 million of fixed rate notes with a coupon of 3.121% maturing on 5 August 2030; and
· €750 million of fixed rate notes with a coupon of 3.278% maturing on 5 August 2033 (together, the Notes).
The Company expects to use the net proceeds of the offering for general corporate purposes.
BNP Paribas, Goldman Sachs International, Morgan Stanley and Société Générale acted as joint book-running managers on the transaction.
The Notes will be issued under the US$10,000,000,000 EMTN programme of the Company and AstraZeneca Finance LLC and admitted to listing on the UK Financial Conduct Authority's Official List and to trading on the London Stock Exchange's Main Market.
The Notes have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the Notes described herein, nor shall there be any sale of these Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AstraZeneca PLC |
Date: 30 July 2024
| By: /s/ Adrian Kemp | |
| Name: Adrian Kemp | |
| Title: Company Secretary |